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In the present study, we aimed to evaluate effects of bladder filling on dose–volume
distributions for bladder, rectum, planning target volume (PTV), and prostate in
radiation therapy of prostate cancer. Patients (n = 21) were scanned with a full
bladder, and after 1 hour, having been allowed to void, with an empty bladder.
Radiotherapy plans were generated using a four-field box technique and dose of
70 Gy in 35 fractions. First, plans obtained for full- and empty-bladder scans were
compared. Second, situations in which a patient was planned on full bladder but
was treated on empty bladder, and vice versa, were simulated, assuming that pa-
tients were aligned to external tattoos. Doses to the prostate [equivalent uniform
dose (EUD)], bladder and rectum [effective dose (D
eff
)], and normal tissue com-
plication probability (NTCP) were compared. Dose to the small bowel was
examined. Mean bladder volume was 354.3 cm3 when full and 118.2 cm3 when
empty. Median prostate EUD was 70 Gy for plans based on full- and empty-
bladder scans alike. The median rectal D
eff
 was 55.6 Gy for full-bladder anatomy
and 56.8 Gy for empty-bladder anatomy, and the corresponding bladder D
eff
 was
29.0 Gy and 49.3 Gy respectively. In 1 patient, part of the small bowel
(7.5 cm3) received more than 50 Gy with full-bladder anatomy, and in 6 patients,
part (2.5 cm3–30 cm3) received more than 50 Gy with empty-bladder anatomy.
Bladder filling had no significant impact on prostate EUD or rectal D
eff
. A minimal
volume of the small bowel received more than 50 Gy in both groups, which is
below dose tolerance. The bladder D
eff
 was higher with empty-bladder anatomy;
however, the predicted complication rates were clinically insignificant. When the
multileaf collimator pattern was applied in reverse, substantial underdosing of the
planning target volume (PTV) was observed, particularly for patients with pros-
tate shifts in excess of 0.5 cm in any one direction. However, the prostate shifts
showed no correlation with bladder filling, and therefore the PTV underdosing
also cannot be related to bladder filling. For some patients, bladder dose–volume
constraints were not fulfilled in the worst-case scenario—that is, when a patient
planned with full bladder consistently arrived for treatment with an empty bladder.
PACS numbers: 87.53.-j, 87.53.Kn, 87.53.Tf
Key words: Prostate cancer, organ motion, radiotherapy, bladder filling
I. INTRODUCTION
aCorresponding author: Vitali Moiseenko, Fraser Valley Centre, British Columbia Cancer Agency, 13750 96th Avenue,
Surrey, BC V3V 1Z2 Canada; phone: 604-877-6000; fax: 604-877-6059; email: vmoiseenko@bccancer.bc.ca
Currently, most cancer centers use full-bladder protocols for radiation therapy of patients with
prostate cancer. The rationale for this choice is well established, being based on better sparing
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of the bladder and small bowel. Currently available technologies for conformal delivery of
radiation to the target, and specifically, for conformal avoidance, may make the advantages of
full-bladder treatment less pronounced. In addition, data about the reproducibility of patient
perception of a full bladder are lacking. However, it is acknowledged that, through the course
of radiation therapy, bladder filling may vary in a systematic manner.(1) Not uncommonly,
either because of advanced age or irritating urinary symptoms, prostate cancer patients find it
difficult to maintain a full bladder during radiotherapy. Filling of the bladder may also signifi-
cantly affect prostate position and have a negative impact on the accuracy of radiotherapy.(2–5)
Empty-bladder treatment has therefore been advocated in patients who require radiation therapy
to the prostate alone. This approach provides better patient comfort and potentially better re-
producibility. Empty-bladder protocols for radiation therapy of the prostate are coming into
use, and the reported bladder toxicity is low so far.(6,7)
Evaluation of treatment plans is based on proper coverage of target volumes by the isodose
lines of choice and sparing of organs at risk (OARs). In prostate radiation therapy, a common
criterion is that the planning target volume (PTV) be fully contained within the 95% isodose
surface. The OARs include femurs, bladder, and rectum. The rectum is often the dose-limiting
organ. Dose–volume criteria and constraints have been established to keep toxicity at accept-
able levels. Specifically, for prostate radiation therapy, Radiation Therapy Oncology Group
criteria (RTOG P0126) are commonly used.
Data sets for conformal therapy outcome with full and empty bladder are both becoming
available, but direct comparison is often complicated by patient selection, treatment protocol,
prescribed dose, and plan acceptance criteria. Data on the effect of bladder filling on prostate
motion in prone(2,5) and supine(8–10) positions are limited. The recent study by Pinkawa et al.(10)
specifically addressed dose–volume distributions as a function of bladder filling with prostate
patients who underwent computed tomography (CT) scanning before radiation therapy and at
4 and 8 weeks of radiation therapy. The authors noted larger variations in full-bladder volume
as compared with empty-bladder volume as treatment progressed. However, that variation did
not affect prostate position.
Ideally, bladder-filling data as it pertains to prostate cancer radiation therapy should be
obtained in a controlled environment that eliminates factors other than bladder filling. A study
specifically designed to evaluate how dose–volume distributions in the PTV, the clinical target
volume (CTV, defined as the prostate only), and the OARs change depending on bladder filling
can therefore provide justification for conformal-field treatment on an empty bladder. In the
present paper, we report the effects of bladder filling on dose distributions for CTV, PTV,
bladder, rectum, and small bowel with prostate patients first scanned on a full bladder and then
on an empty bladder after 1 hour was allowed for voiding.
II. METHODS
A. CT scanning
We enrolled 21 patients aged between 60 and 80 years who received radiation therapy for
prostate cancer at our cancer center. All patients gave consent to participate in the study.
We used a PQ 2000 scanner (Philips Medical Systems, Andover, MA) to obtain full- and
empty-bladder CT scans for each patient. Patients were positioned supine with a foam cushion
for knee support and a Perspex form for ankle support. The first scan was obtained on a full
bladder, patients having been asked to drink 2–3 glasses of fluid (500–750 mL) at least
30 minutes before the scan. Seven fiducial markers were placed on each patient to ensure
consistent setups during the full- and empty-bladder scans (Fig. 1). Markers 3 and 7 were
placed at the level of the right and left greater trochanters; markers 4 and 6 were placed 4.0 cm
anterior to markers 3 and 7, with marker 5 being placed at the anterior midline in the same
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plane; and markers 1 and 2 were placed on the right and left, 5 cm superior to markers 3, 7, and
5. Scanning limits were set from the level of L2/L3 to 4 cm inferior to the ischial tuberosities,
using a 0.5-cm slice index and thickness. Contouring and registration were performed using
Philips AcQsim software. The prostate was contoured on the full-bladder scan while the pa-
tient remained on the CT couch. The virtual simulation software was used to determine the
prostate center of mass, and based on the resulting coordinates, the patient was tattooed using
the laser system. Following the full-bladder scan, the patients were given 1 hour to void before
the empty-bladder CT scan was obtained. The seven external fiducial markers were then used
to register and evaluate the two scans for accuracy.
The entire bladder, rectum (from anal verge to the level at which it turns into sigmoid co-
lon), small bowel (2.5 cm beyond the PTV), and prostate were contoured on each scan. To
eliminate inter-observer variation, the same physician contoured the prostate in all patients.
The PTV was generated by adding a 1-cm three-dimensional (3D) margin to the prostate. The
length of the rectum was noted relative to the inferior set of fiducial markers.
The planning procedure was designed to follow the prostate radiation treatment protocol
currently in use at our cancer center. Patients are aligned using skin tattoos, and portal images
are taken for the first three fractions to verify alignment against bony landmarks.
In the present study, four plans were produced for every patient. These plans were each
assigned a two-letter acronym, the first letter indicating a CT scan to which radiation fields
were applied; the second, the anatomy for which a multileaf collimator (MLC) pattern was
produced. An E stands for empty bladder, and an F, for full bladder. For example, plan EE used
empty-bladder anatomy on CT, and the MLC pattern was specifically designed for that anatomy.
We first used dose–volume histograms (DVH) and biologic indices calculated for FF plans
and for EE plans to consider the dosimetric consequences of treating on an empty bladder and
on a full bladder. Second, we considered situations in which a patient planned on a full bladder
comes for treatment with an empty bladder and vice versa. For example, the EF plan simulates
a situation in which planning was based on full-bladder anatomy, but the patient came for
treatment with an empty bladder. The MLC pattern and the isocenter as derived from the full-
bladder scan were therefore applied to empty-bladder treatment.
To facilitate comparison and interpretation of the treatment plans, we calculated prostate
motion following voiding. For each scan, coordinates for the center of mass of the prostate
were calculated. All coordinates were documented with reference to the intersection of lines
drawn through fiducial markers 3, 5, and 7. Prostate motion in three dimensions was calculated
as the difference in shifts of prostate center of mass relative to the calculated reference point
(Fig. 2). To verify that the calculated prostate motion was not attributable to variation in pros-
tate contouring, we checked prostate volumes in each patient for consistency. For 12 of 21
patients, the difference in prostate volume was less than 2 cm3. For all patients, the difference
was less than 7 cm3.
FIG. 1. Illustration of fiducial marker placement: coronal view (left) and axial view (right).
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Treatment planning was performed using a 3D planning system (Cadplan: Varian Medical
Systems, Palo Alto, CA). A four-field box technique with equally weighted 18-MV beams at
isocenter (gantry 0 degrees, 90 degrees, 180 degrees, 270 degrees) was used. For EE and FF
plans, beams were centered on the prostate. The isocenter coordinates were therefore different
because of the difference in the prostate center-of-mass position. Full- and empty-bladder con-
formal plans were then generated using a 120 MLC system (Varian 21 EX Clinac). Dose
calculations included a modified Batho correction to account for inhomogeneities, and plans
were normalized to the center of the prostate—that is, the isocenter. The minimum dose to the
PTV was 95% of the prescribed dose (7000 cGy in 35 fractions).
When the full-bladder plan was placed onto the empty-bladder anatomy (and vice versa),
the intent was to simulate a situation in which a patient scanned and planned with a full bladder
comes for treatment with bladder empty and receives the treatment planned from the full-
bladder scan. To place the isocenter, as noted above, the documented coordinates were used to
place the field size and MLC shapes from the full-bladder plan onto the empty-bladder anatomy.
Dose calculations were performed using the modified Batho correction and the normalization
from the full-bladder plan. The same number of monitor units (MUs) as calculated for the full-
bladder scan were applied to the empty-bladder plan. A difference of 1 MU was deemed
acceptable as being a result of rounding. On all plans, DVHs were calculated for the bladder,
rectum, small bowel, prostate, and PTV, and these DVHs were exported for analysis.
FIG. 2. Illustration of isocenter location at prostate center of mass and of location of reference point at intersection of
fiducial markers: full bladder (top) and empty bladder (bottom).
B. DVH analysis
The DVHs for rectum and bladder were reduced to single-step histograms—that is, effective
dose to the whole volume—using the power-law method.(11) The values of the parameter
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describing the strength of the volume effects, n, was set to 0.5 for bladder and 0.12 for rec-
tum.(12,13) The effective dose, D
eff
, was calculated using the expression
        , (1)
where D
i
 is the dose to the partial volume V
i
.
The biologic consequences of the dose distribution to prostate were evaluated using the
equivalent uniform dose (EUD).(14) The EUD requires two parameters: surviving fraction after
delivery of 2 Gy (SF
2
), which was set to 0.65(15); and α/β ratio, which was set to 1.5 Gy.
Smaller SF
2
 values—for example, SF
2
 = 0.5—were used in model calculations accounting for
tumor heterogeneity in radiosensitivity.(16) In that case, tumor response is dominated by a ra-
dioresistant tail. Carlson et al.(17) recently summarized linear-quadratic radiosensitivity
parameters reported in both in vitro and in vivo studies. If the in vivo parameters are translated
to SF
2
, values in the range 0.6–0.85 can be obtained, consistent with the SF
2
 of 0.65 used in the
present study. The NTCP was calculated using the Lyman–Kutcher–Burman formalism,(11,12)
with model parameters set to those reported in Burman et al.(12)
III. RESULTS
Fig. 3 shows histograms for empty- and full-bladder volumes in the study patients. Mean full-
bladder volume was 354.3 cm3 (range: 154.9–601.6 cm3; median: 349.9 cm3), and mean
empty-bladder volume was 118.2 cm3 (range: 48.8–351.6 cm3; median: 104.6 cm3). On aver-
age, bladder volume decreased by 236 cm3 after patients were allowed to void. Table 1 shows
the full data for prostate, bladder, and rectum volumes. Notably, except for bladder volume,
other organ volumes were not affected by the full or empty state of the bladder. That finding
FIG. 3. Distribution of bladder volume (empty and full bladder) for 21 patients.
TABLE 1. Mean volume (standard deviation) of considered organs with full and empty bladder, in cubic centimeters
Bladder Rectum Prostate
Empty bladder 118.2 (67.9) 89.5 (37.7) 46.3 (20.7)
Full bladder 354.3 (140.5) 88.4 (34.3) 46.3 (20.8)
60 Moiseenko et al.: Effect of bladder filling on doses... 60
Journal of Applied Clinical Medical Physics, Vol. 8, No. 1, Winter 2007
means that, for organs other than bladder, differences between dose distributions in EE and FE
plans and in FF and EF plans can be attributable only to organ motion relative to external
markers and not to changes in organ volumes. In contrast, for bladder, these differences—and
particularly the differences between EE and FF plans—result from bladder volume changes.
Prostate motion was examined. Fig. 4 shows a scatter graph for shifts in the position of the
prostate center of mass in three dimensions. The prostate shifts were defined as change in the
coordinates of the prostate center of mass relative to the external fiducial markers. The most
pronounced shifts were in the superior–inferior and anterior–posterior dimensions. Table 2
further illustrates that finding.
Although prostate motion was noted between full- and empty-bladder scans for some pa-
tients, no systematic movement in any direction was observed. The largest shifts for specific
patients were 1.24 cm in the posterior direction, 0.6 cm in the anterior, 0.52 cm in the inferior,
and 0.50 cm in the superior. Of 21 patients, 10 showed prostate shifts in excess of 0.5 cm in one
of the directions. On average, the shifts were insignificant, and no patient showed prostate
shifts larger than 0.5 cm in more than one direction. Change in bladder volume did not corre-
late with prostate shifts; Table 3 shows the linear regression results. In contrast, rectal filling
strongly correlated with prostate shifts in the anterior–posterior direction. Table 3 also shows
those results.
Empty- (EE) and full-bladder (FF) plans were both designed to ensure coverage of the
PTV with the 95% isodose surface, with no dose–volume constraints applied for normal
tissue. Median prostate EUD for the full-bladder scans was 70 Gy (range: 69.7–70.5 Gy;
TABLE 2. Prostate shifts following bladder voiding, in centimeters
Shift direction Median Mean Standard deviation Largest shift
Left(+)/Right(–) –0.04 –0.02 0.17 0.31 Left 0.25 Right
Anterior(+)/Posterior(–) –0.01 –0.05 0.45 0.6 Anterior 1.24 Posterior
Superior(+)/Inferior(–) –0.01 –0.10 0.30 0.50 Superior 0.52 Inferior
FIG. 4. Three-dimensional representation of prostate shifts following bladder voiding.
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mean: 70.0 Gy) as compared with 70 Gy (range: 69.7–70.6 Gy; mean: 70.1 Gy) for the empty-
bladder scans. That observation shows that the planning objective to contain the entire PTV
within a 95% isodose surface was achieved equally well for both scans. Note that, to clearly
identify and quantify the dosimetric consequences of bladder filling for normal tissues, no
normal-tissue constraints were applied in treatment planning.
Fig. 5 shows effective rectum doses for full- (FF) and empty-bladder (EE) scans. The me-
dian rectal D
eff
 for the full-bladder scans was 55.6 Gy (range: 53.4–61.4 Gy; mean: 55.7 Gy) as
compared with 56.8 Gy (range: 52.0–61.9 Gy; mean: 56.5 Gy) for the empty-bladder scans.
Although more points fall below the 45-degree line, indicating better rectal sparing for full-
bladder scans, the difference is marginal. The two lines drawn through the 60-Gy points on
both axes show the tolerance dose corresponding to 5% risk of complications, based on pub-
lished data for tolerance dose (TD
5/5
).(13) For 1 patient, the rectum D
eff
 was not contained
within the area inside the dashed lines, indicating that the risk of rectal complications was
excessive. An alternative plan was produced for this patient’s actual treatment.
Fig. 6 presents the bladder D
eff
 data. Expectedly, better bladder sparing was achieved when
full-bladder (FF) scans were used. For the full-bladder scans, the median bladder D
eff
 was 29.0
Gy (range: 22.0–51.8 Gy; mean: 32.4 Gy) as compared with 49.3 Gy (range: 34.2–59.6 Gy;
mean: 48.1 Gy) for the empty-bladder scans. For some patients, the change in effective dose
was as high as 30 Gy. However, all the points were contained within the area set by the TD
5/5
lines,(12,13) and the NTCP values did not exceed 2% for either group.
TABLE 3. Correlation between prostate shift and changes in bladder and rectal volumes
Shift direction R2 P
Change in bladder volume
Superior/inferior 0.034 0.423
Anterior/posterior 0.010 0.660
Lateral 0.012 0.633
Change in rectal volume
Superior/inferior 0.034 0.425
Anterior/posterior 0.410 0.002
Lateral 0.076 0.225
FIG. 5. Effective dose (D
eff
) to rectum for empty- and full-bladder computed tomography scans. Dashed lines indicate
tolerance dose (TD
5/5
) as reported by Emami et al.(13)
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Because only a portion of small bowel was contoured, dose–volume data for the whole
organ are not available. Fig. 7 shows absolute volumes receiving more than 15 Gy.(18) In 8
empty-bladder (EE) and 15 full-bladder (FF) scans, no part of the small bowel received more
than 15 Gy. Better small-bowel sparing can be achieved if full-bladder scans are used; how-
ever, the absolute volume of small bowel receiving doses greater than 15 Gy is small—less
than 120 cm3 in all cases. If a 50-Gy cutoff dose had been applied,(13,19) part of the small
bowel would have received more than 50 Gy in 1 patient with a full bladder (7.5 cm3), and in
6 with an empty bladder (2.5 cm3–30 cm3). The largest volume receiving more than 50 Gy
was only 30 cm3.
Fig. 8 shows how PTV coverage is affected if the MLC shape produced for an empty-
bladder scan is applied to full-bladder anatomy (FE) and vice versa (EF). The dashed lines
indicate V
95
—that is, 95% of the PTV receiving 95% of the prescribed dose. As planned, V
95
 =
100% by design, with the MLC adjusted to tightly conform to the PTV so as to minimize the
dose to the surrounding normal tissues. For patients with a prostate shift larger than 0.5 cm
FIG. 6. Effective dose (D
eff
) to bladder for empty- and full-bladder computed tomography scans. Dashed lines indicate
tolerance dose (TD
5/5
) as reported in Emami et al.(13)
FIG. 7. Small bowel volumes receiving more than 15 Gy for empty- and full-bladder computed tomography scans.
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relative to external fiducial markers, the PTV can be severely underdosed. Notably, all 5
patients receiving less than 95% of prescription dose to less than 95% of the PTV had
prostate shifts larger than 0.5 cm. For patients who showed small shifts relative to fiducial
markers, underdosing of the PTV, if any, was also small. In terms of PTV coverage, FE
and EF plans were equally detrimental. Although Fig. 8 uses the terms “empty” and “full”
bladder, it was not bladder filling that caused the prostate (and consequent PTV) shifts.
These findings are therefore more reflective of a change in anatomy within approximately
1 hour.
For patients with a large prostate shift, the PTV coverage was compromised; however,
underdosing of prostate itself did not result (Fig. 9). If the EUD did not change at all, the point
would fall on the dashed line. Points below this line indicate patients who will receive an EUD
below that planned. The upper panel shows how the EUD would change if a patient planned on
an empty bladder came for treatment with a full bladder (FE). None of the patients showed an
EUD below 69.5 Gy for an empty-bladder MLC applied to full-bladder anatomy. For the oppo-
site (EF) situation, 1 patient showed an EUD of 69 Gy. However, that patient’s planning EUD
was 69.7 Gy. Overall, prostate coverage is acceptable, which proves that the PTV margins used
are adequate even for large shifts.
Fig. 10 shows how the effective dose to rectum changes in FE (upper panel) and EF (lower
panel) plans. The dashed lines show the TD
5/5
 for the whole organ.(13) For 1 patient, the plan-
ning D
eff
 exceeded acceptable dose–volume constraints. In clinical practice, this plan would
have been rejected, and an alternative beam arrangement would have been considered. On 5
occasions, patients whose planning D
eff
 had been less than 60 Gy moved above the 60 Gy
threshold. Although the largest changes in D
eff
 were seen for patients with prostate shifts larger
than 0.5 cm in one of three directions, a large shift is not prerequisite. On 2 of 5 occasions when
the 60-Gy D
eff
 threshold was exceeded, the shift was less than 0.5 cm.
Fig. 11 shows how bladder D
eff
 would change if a patient who was planned on an empty
bladder were to be treated with a full bladder (FE plan, upper panel) and vice versa (EF plan,
lower panel). This case is the only one in which a change in dose–volume statistics can be
related to organ change rather than to changes in anatomy not related to bladder filling (as
appears to be the case for prostate and rectum). As expected, for patients who were planned on
an empty bladder, better bladder sparing is achieved if the patient arrives for treatment with a
full bladder. On the other hand, substantial detrimental change in D
eff
 may occur if a patient
FIG. 8. Planning target volumes (Vs) receiving at least 95% of the prescription dose. As planned, V
95
 = 100%. MLC =
multileaf collimator; AP = anterior–posterior; SI = superior–inferior.
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planned with a full bladder arrives for treatment with an empty bladder. The lower panel in Fig.
11 shows that, for some patients, the effective dose changes by as much as 30 Gy, although the
TD
5/5
(13) is never exceeded.
FIG. 9. Prostate equivalent uniform dose (EUD) for situations in which a multileaf collimator (MLC) pattern designed for
one scan was applied to a different scan. AP = anterior–posterior; SI = superior–inferior.
FIG. 10. Rectal effective dose (D
eff
) for situations in which a multileaf collimator (MLC) pattern designed for one scan was
applied to a different scan. Dashed lines indicate tolerance dose (TD
5/5
) as reported in Emami et al.(13) AP = anterior–
posterior; SI = superior–inferior.
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IV. DISCUSSION
In the present study, we looked at the impact of bladder filling on prostate radiotherapy dosim-
etry. Although the patients were given clear instructions how to prepare for the full-bladder and
empty-bladder scans, the range of bladder volumes in both series was very wide, indicating sig-
nificant variation in individual bladder volume and possibly in individual perception of bladder
fullness. Prostate shifts are apparent between the full-bladder and empty-bladder scans. Magni-
tude of the prostate shifts is consistent with the results from other institutions.(2–5) In most cases,
magnitude of the prostate shift relative to the external fiducial markers is small (the mean shifts
being less than 0.1 cm in any direction), but the shift can exceed 0.5 cm for a specific patient.
Prostate motion showed no consistent correlation with bladder filling in the present study.
Prostate EUDs were not significantly different when planned either on a full-bladder scan or
an empty-bladder scan. That finding is not unexpected, because the radiotherapy plan is designed
to encompass the PTV optimally, whether the planning CT is done with a full or empty bladder.
The rectal D
eff
 was also not affected by bladder state, full or empty, during the acquisition of the
planning CT. That finding implies that the irradiated rectal volumes are not significantly affected
by bladder filling, although the possibility that rectal shape and size (potentially affected by rectal
peristalsis) can be different between the empty- and full-bladder scans is not excluded.
Although doses to the small bowel may be slightly higher in the empty-bladder dosimetry,
they are within tolerance.(13,19) Letschert et al.(19) reported a correlation between small-bowel
volume receiving 50 Gy or higher and bowel complications. The actuarial 5-year estimate of
chronic diarrhea varied from 31% in patients with irradiated small-bowel volumes below
77 cm3 to 42% in patients with irradiated volumes above 328 cm3. In the present study, the
maximum small-bowel volume receiving more than 50 Gy was just 30 cm3.
FIG. 11. Bladder effective dose (D
eff
) for situations in which a multileaf collimator (MLC) pattern designed for one scan
was applied to a different scan. Dashed lines indicate tolerance dose (TD
5/5
) as reported in Emami et al.(13) AP = anterior–
posterior; SI = superior–inferior.
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Our results clearly demonstrate that bladder sparing is indeed significantly improved for
patients treated on a full bladder. However, bladder complication rates are fairly low, with an
estimated NTCP of less than 2% in the full-bladder and empty-bladder cases. In institutions in
which an empty bladder is used as part of the prostate radiotherapy protocol,(6,7) the published
genitourinary (GU) toxicity has been low and comparable with results from other institutions.
The key question is not whether DVHs for a full bladder are superior to those for an empty
bladder, but rather whether the empty-bladder DVHs are clinically acceptable. If the RTOG
P0126 guidelines are followed, then constraints on bladder DVHs must obey these require-
ments: V
80
 < 15%, V
75
 < 25%, V
70
 < 35%, and V
65
 < 50%, where V
x
 is the percentage volume
receiving a dose of at least x Gy. Because the prescription dose is 70 Gy, only constraints for
doses 70 Gy or less could have been violated. Of the 21 patients involved in the present study,
the EE plans for only 2 showed DVHs that did not obey the D
65
 constraint.
Although bladder DVH guidelines(6,7) have been suggested (RTOG P0126), most of the
published results do not support a correlation between bladder DVH and GU toxicity.(20–24) We
suspect that, although bladder dose is related to GU toxicity, the critical organs may be the
bladder neck itself and the urethra, which often are not analyzed in external-beam radiotherapy
data. In addition to the known daily variation of bladder filling, bladder DVH alone may not be
the ideal factor for GU toxicity correlation. The combination of bladder and bladder neck DVH
with urethral DVH is likely to be a better model in correlations of GU toxicity.
The presented data for MLC pattern, when applied in reverse, show an extreme case when
the MLC pattern designed for one scan is applied to a different scan throughout treatment. In
reality, if a patient is planned with bladder full, but is not able to maintain fullness throughout
treatment, the process will be very gradual. Therefore, the data presented in Fig. 11 have to be
treated as the worst-case scenario.
A systematic reduction in bladder volume through the course of prostate radiation therapy
has been observed clinically. Zellars et al.(1) reported that bladder volume in 24 prostate pa-
tients treated supine with a full-bladder protocol decreased to 51% of pretreatment volume
after 4–5 weeks of radiation therapy.
Although the D
eff
 threshold corresponding to TD
5/5
 was never exceeded for the patients
considered in the present study, the proposed RTOG P0126 DVH restrictions are in some
cases violated. Specifically, for the patient who showed a change in bladder D
eff
 from 30 Gy
to 64 Gy, the D
65
—that is, the bladder volume receiving more than 65 Gy—was 74%, well in
excess of the less than 50% in the RTOG guidelines. Notably, this patient showed a very large
change in bladder volume—from 419 cm3 to 90 cm3. Conceivably, some patients may experi-
ence significant changes in bladder volume (for example, because of urinary symptoms), thereby
putting them at risk of bladder complications.
Changes in dose distributions in organs and volumes other than bladder have to be treated
with care. Although we referred to scans or MLC patterns as “full-bladder” and “empty-blad-
der,” organs outside of the bladder showed no directional motion or change of volume because
of bladder filling. In patients who showed shifts in prostate location larger than 0.5 cm in any
one direction, PTV coverage was compromised. However, compromised dose delivery to the
prostate did not result.
Although change in rectal dose distribution cannot be attributed to bladder filling, such
change is quite marked. No directional preference was noted, whether an empty-bladder MLC
pattern was applied to full-bladder anatomy or vice versa: rectal D
eff
 was reduced in some
patients and increased in others. Patients with large prostate shifts also tended to show larger
changes in rectal D
eff
; nevertheless, 1 patient who showed no shift in excess of 0.5 cm showed
a significantly changed rectal dose distribution when his empty-bladder MLC pattern was ap-
plied to his full-bladder anatomy. If RTOG guidelines for rectal DVH were to be applied, then
the plan would not have been acceptable. This patient’s V
60
—that is, partial rectal volume
receiving at least 60 Gy—changed from 34% to 48% when the empty-bladder MLC pattern
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was applied to the full-bladder scan. The RTOG guideline is less than 50%. Similarly, V
65
changed from 27% to 43%, in violation of the 35% guideline, and V
70
 changed from 7% to
23%, close to violating 25% guideline. This finding shows that, within a span of 1 hour,
patient anatomy can change to the extent that a plan deemed to obey normal-tissue toler-
ance guidelines no longer complies with those guidelines, reinforcing the possibility that
significant geometric errors, in particular systematic errors, may put patients at increased
risk of complications.
V. CONCLUSIONS
Bladder filling has no significant impact on prostate EUD or rectal D
eff
. In both full- and
empty-bladder scans, only a minimal volume of small bowel received more than 50 Gy, which
is below dose tolerance. The bladder D
eff
 is higher with an empty bladder; however, with the
currently available NTCP data, the predicted complication rates are clinically insignificant.
Substantial changes in dose distributions were noted if, with beams aligned to external fiducial
markers, the MLC pattern designed for an empty-bladder scan was applied to full-bladder
anatomy and vice versa. Substantial PTV underdosing was shown. The underdosing was par-
ticularly pronounced for patients with prostate shifts in excess of 0.5 cm in any single direction
relative to external fiducial markers. Dose to the prostate itself was not compromised. Changes
in dose distributions to the prostate and rectum in EF and FE plans cannot be correlated with
bladder filling. For the EF and FE plans, dose distributions in rectum and, particularly, in
bladder change substantially. For some patients, in the worst-case scenario, bladder tolerance
may be exceeded for the EF plan—that is, when a patient planned on a full bladder arrives for
treatment with an empty bladder throughout treatment.
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